Actualités et vidéos - MYLAN N.V. - Page 2

Mylan and Sesame Workshop Partner to Provide Socio-Emotional Support Resources to Families Impacted by COVID-19 - Free digital content kits featuring beloved Sesame Street characters will be made available through a US$1 million donation from Mylan - PR Newswire HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Aug. 12, 2020 HERTFORDSHIRE, England, PITTSBURGH and NEW YORK , Aug. 12, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Sesame Workshop, the non-profit educational organization behind...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”), of the important August 25, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Mylan investors under the federal securities laws. To join the Mylan class action, go to http://www.rosenlegal.com/cases-register-1889.html or call Phillip Kim, Esq. toll-free at...

Mylan Reports Strong Second Quarter and First Half 2020 Results and Updates 2020 Guidance PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Aug. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and six months ended June 30, 2020. Second Quarter 2020 Financial Highlights Total revenues of $2.73 billion , down 4%, down 2% on a constant currency basis, compared to the prior year period. Revenue...

Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 22, 2020 HERTFORDSHIRE, England and PITTSBURGH , July 22, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financial results on Thurs., Aug. 6 , before the open of the U.S. financial markets. The company also will host a webcast at 10:30 a.m. ET on Aug. 6 to discuss the results. The...

ROSEN, A TOP RANKED INVESTOR FIRM, Reminds Mylan N.V. Investors of Important August 25 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYL PR Newswire NEW YORK, July 21, 2020 NEW YORK , July 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019 , inclusive (the "Class Period"), of the important August 25,...

Viatris Reveals Branding to Reflect New Company's Transformative Strategy Announcement follows Mylan shareholder approval of Mylan's combination with Pfizer's Upjohn PR Newswire HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, July 9, 2020 HERTFORDSHIRE, England , PITTSBURGH and NEW YORK , July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Upjohn, a division of Pfizer, today unveiled the logo and branding for VIATRIS ™ , the new company that will be formed by combining Mylan and Upjohn....

Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp) PR Newswire HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 HERTFORDSHIRE, England and PITTSBURGH and TOKYO , July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio ® (adalimumab-fkjp), a biosimilar to AbbVie's Humira ® (adalimumab), for the treatment of...

Mylan Initiates Voluntary Nationwide Recall of One Lot of Daptomycin for Injection, Due to the Presence of Particulate PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 7, 2020 HERTFORDSHIRE, England and PITTSBURGH , July 7, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S.-based Mylan Institutional LLC business is conducting a voluntary nationwide recall to the consumer level of one lot of Daptomycin for Injection, 500 mg/vial due to the presence of particulate...

Mylan Secures Regulatory Approval for Remdesivir Lyophilized Powder for Injection 100 mg/vial in India for Restricted Emergency Use in COVID-19 Patients PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BANGALORE, India, July 6, 2020 HERTFORDSHIRE, England and PITTSBURGH and BANGALORE, India , July 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the Drug Controller General of India (DCGI) has approved its remdesivir 100 mg/vial for restricted emergency use in India as...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”), of the important August 25, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Mylan investors under the federal securities laws. To join the Mylan class action, go to http://www.rosenlegal.com/cases-register-1889.html or call Phillip Kim, Esq. toll-free at...

MYL SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Mylan N.V. Investors With Losses Exceeding $11,000,000 of Class Action and Lead Plaintiff Deadline: August 25, 2020 PR Newswire NEW YORK, July 3, 2020 NEW YORK , July 3, 2020 /PRNewswire/ --Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mylan N.V. ("Mylan" or the "Company") (NASDAQ: MYL) and certain of its officers, on behalf of shareholders who...

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Mylan N.V. ("Mylan" or the "Company") (NASDAQ: MYL) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Mylan securities between February 16, 2016 and May 7, 2019, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/myl . This class action seeks to recover damages...

ROSEN, A LONGSTANDING AND TOP RANKED GLOBAL INVESTOR FIRM, Announces Filing of Securities Class Action Lawsuit Against Mylan N.V.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - MYL PR Newswire NEW YORK, June 30, 2020 NEW YORK , June 30, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019 ,...

Mylan Shareholders Overwhelmingly Approve Proposed Combination with Upjohn 99.6% of Shares Voted in Favor of the Transaction PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 30, 2020 HERTFORDSHIRE, England and PITTSBURGH , June 30, 2020 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company's extraordinary general meeting of shareholders....

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mylan N.V. (“Mylan” or “the Company”) (NASDAQ: MYL ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 16, 2016 and May 7, 2019, inclusive (the ''Class Period''), are encouraged to contact...

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May 7, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Mylan investors under the federal securities laws. To join the Mylan class action, go to http://www.rosenlegal.com/cases-register-1889.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email...

Mylan Wins District Court Decision Against Biogen's Tecfidera® Patent Mylan achieves key milestone to provide U.S. multiple sclerosis patients with more affordable generic version of Biogen's Tecfidera® capsules Biogen's asserted claims of ᾿514 method patent found invalid Win clears legal pathway to launch upon FDA approval PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 18, 2020 HERTFORDSHIRE, England and PITTSBURGH , June 18, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today...

Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn PR Newswire HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, June 18, 2020 HERTFORDSHIRE, England , PITTSBURGH and NEW YORK , June 18, 2020 /PRNewswire/ -- Upjohn Inc. ("Newco"), a wholly-owned subsidiary of Pfizer Inc. ("Pfizer") (NYSE: PFE), Upjohn Finance B.V. ("Finco"), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. ("Mylan") (Nasdaq: MYL) today announced the pricing of a...

Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection) FDA approval marks a significant milestone to help increase access and affordability of insulin for the millions of Americans living with diabetes[1] Comprehensive data from the INSTRIDE studies confirmed the efficacy, safety and immunogenicity of Semglee in comparison to Lantus® Semglee to be offered in vial and pen presentations PR Newswire HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June...

Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept PR Newswire HERTFORDSHIRE, England, PITTSBURGH and MUMBAI, India, June 4, 2020 HERTFORDSHIRE, England , PITTSBURGH and MUMBAI, India , June 4, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Lupin Limited (Lupin) today announced that the European Commission (EC) has granted marketing authorization for Nepexto ® , a biosimilar to Enbrel ® (etanercept), for all indications of the reference product...